A review in Respirology finds that four distinct biological mechanisms drive obstructive sleep apnea in different patients, and that matching treatments to each mechanism could transform care — especially for the millions who abandon CPAP.
A large European clinical trial found that sulthiame, an existing epilepsy medication, reduced breathing interruptions during sleep by up to 47% in patients with moderate to severe obstructive sleep apnea, raising hopes for a pharmaceutical alternative to CPAP therapy.
Research by a 17-year-old student recognized in the Regeneron Science Talent Search found that over 25% of surveyed high school students reported symptoms of sleep paralysis, a rate consistent with studies of college-aged populations and raising questions about the role stress plays.
A clinical trial of more than 300 participants found that SHUTi OASIS, the first digital insomnia program designed specifically for adults over 55, produced sleep improvements that lasted at least a year—two to three times better than standard online education.
A study from Spain found that people with multiple sclerosis are about twice as likely to develop restless legs syndrome as those without the disease, with family history and pyramidal symptoms increasing the risk further.
A new study suggests that tracking daytime symptoms like fatigue and mood through smartphone apps may be more effective than traditional sleep diaries for determining whether insomnia medications are working.
Pharmaceutical company Apnimed plans to file for FDA approval of AD109 in early 2026 after the drug met its primary endpoint in a second Phase 3 trial, potentially offering relief to patients who struggle with CPAP therapy.